NKTR Nektar Therapeutics
NKTR Nektar Therapeutics
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 bear converging
POC $69.63 · VWAP $63.20 · -43.4% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, Officer sold $43.5K, Aug 20
Coverage
3 watchlists
NKTR Price Structure
Loading timeframes…
Peers
Every watchlist NKTR belongs to, members best 30-day change first — NKTR highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@biotech-scan
@monster-discoveries
Reported the quarter ending 2026-06-30: revenue $10M, diluted EPS -$1.23, net income -$41M (SEC filing). Across the print the stock moved +4.6% (close before → first close after).
full note →Against street estimates
How NKTR's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about NKTR from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 14 days ago · Oct 3
- Nektar Therapeutics (NKTR) Q2 2026 Earnings Report
- Nektar Therapeutics (NKTR) Dropped, So What Is Driving ...
- Nektar Stock Price Today | NASDAQ: NKTR Live - Investing.com
- NKTR Q2 2026 Earnings Report on 8/13/2026 - MarketBeat
- http://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-reports-first-quarter-2026-financial-results
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
NKTR research tape
73 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.